Atomoxetine
Two atomoxetine products sit on this shelf: Strattera, the brand-name version from Eli Lilly, and Axepta from Torrent Pharmaceuticals. Both come as tablets in 10 mg, 18 mg, 25 mg and 40 mg strengths, listed for Attention Deficit Hyperactivity Disorder.
Key points
- Atomoxetine carries a boxed warning: in short-term trials, suicidal ideation appeared in 0.4% of children and adolescents taking it (5 of 1,357), compared with none among 851 on placebo. No suicides occurred.
- Atomoxetine is a norepinephrine reuptake inhibitor, a mechanism separate from stimulant medications. The label lists it for ADHD in children and adults, and states it is not approved for major depressive disorder. Both products are listed under ADHD & Focus.
- Drugs that reduce stomach acid, such as antacids and omeprazole, had no effect on atomoxetine absorption.
Common questions about Atomoxetine
What should I watch for when starting atomoxetine?
Patients starting atomoxetine should be monitored closely for suicidal thinking, worsening symptoms, or unusual changes in behaviour. Families and caregivers should watch for these signs and report them to the prescriber. Co-existing conditions alongside ADHD may themselves raise the risk of suicidal thoughts.
Why does atomoxetine come in four strengths?
A prescriber can match the dose to each patient’s needs across the 10 mg, 18 mg, 25 mg and 40 mg range. The label covers both children and adults with ADHD.